Across the (Psychiatric) Universe

Psychiatric TimesVol 34 No 4
Volume 34
Issue 4

At Psychiatric Times, it has long been our goal to publish cutting-edge information from the frontiers of psychiatry. In this this spirit, we welcome Dr. Thomas G. Schulze, one of the world’s leading experts on psychiatric genetics to our Editorial Board.

Dr. Thomas G. Schulze

Dr. Thomas G. Schulze


A Message from the Editor

It has long been our goal to bring you cutting-edge information from the frontiers of psychiatry. For the past couple of years, we have been collaborating with a number of psychiatric societies* and publishing articles from these groups in almost every issue. We hope this information is helping you keep up-to-date across the spectrum of your multifaceted field.

It is in this spirit that we welcome one of the world’s leading experts on psychiatric genetics to our Editorial Board. It is both an honor-and a pleasure-to welcome Dr. Thomas G. Schulze, who joins the distinguished psychiatrists who now grace our masthead.

Dr. Schulze is Director of the Institute of Psychiatric Phenomics and Genomics at Ludwig-Maximilian University in Munich, Germany. He also holds a visiting professorship with the Department of Psychiatry and Psychotherapy at the University Medical Center in Göttingen, Germany. A resident of both Germany and the US, he has adjunct positions with the National Institute of Mental Health in Bethesda, and with the Department of Psychiatry and Behavioral Sciences at Johns Hopkins University in Baltimore. Dr. Schulze is President of the International Society of Psychiatric Genetics, past President of the American Psychopathological Association, and Chair of the Section on Genetics in Psychiatry of the World Psychiatric Association.

In future issues, we look forward to bringing you insights about current achievements of psychiatric genetics from Dr. Schulze and how they may influence the future treatment of patients-as well as the various challenges that lie ahead. These include the clinical usefulness of genetic testing or more broadly the ethical, legal, and societal issues that surround large-scale genomic research.

The members of our Editorial Board aren’t just figureheads. Led by Drs. Allan Tasman and Michelle Riba, each one helps guide our editorial ship . . . by suggesting topics, serving as peer reviewers, contributing articles, and giving us their frank appraisal of every issue. Their goal is to bring you a publication that delivers timely, engaging, authoritative-and useful-information from all corners of psychiatry.

We hope you like what you’ve been reading.

*Since 2016, we have published articles from the Academy of Psychosomatic Medicine, American Association for Geriatric Psychiatry, American Academy of Addiction Psychiatry, American Association of Community Psychiatrists, National Network of Depression Centers, Group for the Advancement of Psychiatry, and The American Academy of Psychoanalysis and Dynamic Psychiatry.

Related Videos
“What we’re striving to do is conquer the unmet needs that are still here with treating ADHD, especially from a medication standpoint.”
© 2023 MJH Life Sciences

All rights reserved.